38 results about "Severe trauma" patented technology

A hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied through a mixing needle and / or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, it produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The fibrin components are produced by a novel dialysis method which does not present thrombin to the immune system and can be maintained in solution for six weeks without significant proteolytic degradation.

ClotFoam is a surgical sealant and hemostatic agent designed to be used in cases of non-compressible hemorrhage. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and / or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade.The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue.

ClotFoam is a sealant and hemostatic agent for use in cases of non-compressible hemorrhage for moderate to severe bleeding. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and / or a spray injection method following intracavitary severe trauma or surgery. Its crosslinking technology generates an adhesive scaffold that carries a fibrin sealant required for hemostasis. Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The composition is biocompatible and non-inflammatory. The invention uses fibrin monomer polymerized by a change of pH as active sealing component. The viscoelastic properties of the foam as well as the rapid formation of a fibrin clot ensure that the sealant remains at the site of application without being washed away by blood.

The implant is a fixation device shaped in the form of a plate for use in the fixation and stabilization of the thoracolumbar spine. The design and the configuration of the device allows for an anatomic fit of the plate in the spine. The improved fixation allows for an anatomical and biomechanicat advantage in stabilizing thoracolumbar spine trauma both in a primary fashion and / or in conjunction with vertebral body replacement. Its anatomic design allows the application of an ingrowth surface at the host / implant interface and encourages an additional point of fixation in cases at high risk for delayed or non-union such as severe trauma or malignancy. The thoracolumbar spine plate is anatomically designed to fit snugly against the thoracolumbar vertebral bodies through a twist around the Z (longitudinal) axis of the generally rectangular plate.

A method for determining the existence and the amount of soluble fibrin contained in a specimen fluid is provided. The method includes the steps of precipitating soluble fibrin out of the opaque specimen fluid, aggregating the soluble fibrin precipitates in a limited region of a transparent container so as to render the precipitates optically detectable in the opaque specimen fluid, and optically detecting the precipitates. The amount of soluble fibrin may be determined by measuring the time from the addition of the precipitating regent to the detection of the soluble fibrin precipitates. Methods of the present invention allow one to measure soluble fibrin in whole blood, and therefore render the test useful in the operating room under conditions of major surgery and in the presence of severe trauma wherein DIC is likely to supervene.

Compound of formula (I)wherein:R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or ═O; andR2 is H, methyl or ethyl;and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The invention discloses an application of (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone in preparing medicines used for treating pain diseases. Related studies show that the compound has a significant abirritation, and can effectively reduce pain reactions caused by thermal stimulation and chemical stimulation. The compound can be used for preparing medicines used for relieving acute pains, headache, toothache, neuralgia, tumor-type pain, and pains caused by inflammatory diseases of muscles and bone joints, wherein the acute pains are caused by severe injury, burns, etc., and the pains caused by the inflammatory diseases of the muscles and the bone joints comprise rheumatic and rheumatoid arthritis pains, dysmenorrheal and other inflammatory pains, and neuropathic pains.

Biomarkers and methods of using the same to aid in the diagnosis, prognosis and treatment of critically ill patients are disclosed. In particular, the present invention relates to the use of biomarkers for prognosis of death in critically ill patients suffering from sepsis, severe trauma or burns.

The invention discloses a method for preparing modified starch hemostatic microspheres. The method is characterized in that with starch as a medium material, succinic anhydride modification and chemical crosslinking are conducted on the starch, and the starch is prepared into the microspheres, so that the surface contact area is greatly increased, the method facilitates increasing the liquid absorption rate and speed of the starch, and the stability of the hemostatic microspheres prepared by the method is high; moreover, by utilizing the characteristic that the hemostatic microspheres quicklyabsorb blood and rapidly swell, the blood vessels are quickly and centralizedly blocked, and the effect of quick hemostasis is achieved; since the hemostasis effect of the modified starch hemostatic microspheres is physical, no chemical or pharmaceutical reagent is used in the function process, the modified starch hemostatic microspheres are safe and reliable and have no side effects on the livingbodies, and the modified starch hemostatic microspheres are not only suitable for hemostasis during in-vivo or body-surface bleeding but also suitable for effective hemostasis for severe traumas caused by sudden disasters or life-threatening major bleeding caused by clinically large surgery.

The present invention belongs to non-specific immunoenhancing drugs, which is an oral preparation of arginine acetate. Road will not produce irritation, long-term use will not produce hyperchloremia. As an immune-enhancing drug, it is mainly used clinically for patients with severe trauma, burns, major surgery, and cancer patients whose immune function is suppressed after radiotherapy and chemotherapy. It is safe, convenient, and effective.